Tilt announces partnership with MSD for immunotherapy clinical trials

By Anusha  | Date: 2022-09-28

Tilt announces partnership with MSD for immunotherapy clinical trials

Tilt Biotherapeutics Ltd. has recently announced a partnership deal with MSD (trade name of Merck & Co.), wherein the two pharmaceutical giants would focus on combining their resources toward evaluating a new clinical trial on TILT-123.

For those unaware, TILT-123 is the company’s oncolytic adenovirus with two human cytokines which will also include a component of Keytruda, commonly known as pembrolizumab. The treatment plan is reportedly a part of MSD’s anti-PD-1 therapy procedure.

The treatment would involve actively utilizing armed oncolytic adenoviruses with cytokines and other molecules to amplify a patient’s T-cell immune response, thereby facilitating a faster identification and destruction of existing cancer cells.

Notably, the phase 1 open label, dose escalation trial would be conducted on 12-24 patients suffering from immune checkpoint inhibitor refractory non-small cell lung cancer (NSCLC). The clinical trial is expected to capitalize on the immense data available with the company, regarding the usability of TILT-123.

Interestingly, TILT-123 has been undergoing trials for several other indicators. Thus far, these trials have showcased promising results for intravenous usability, thereby allowing the company to expand its portfolio on existing trials.

Elaborating on the development, Akseli Hemminki, Tilt’s Chief Executive Officer claimed that the company has successfully initiated clinical trials for different cancer types such as ovarian cancer, melanoma, and head & neck cancer across the United States and Europe. Several other clinical trials, including the one ongoing with MSD, will be expected to be on floors in the coming months.

In addition, he asserted that their oncolytic viruses are actively showcasing their potential in increasing the anti-tumor advantages of checkpoint inhibitors across a wide variety of cancers that require improved treatment plans.

TILT, headquartered in Helsinki, Finland, was founded in 2013 as a spin-off from the University of Helsinki. Angel investors including Business Finland, and the European Innovation Council (EIC) along with Finnish Industry Investment (TESI), and Lifeline Ventures, have all made a significant contribution to its funding.


SourceCredits: -   https://www.pharmatimes.com/news/tilt_collaborates_with_msd_on_immunotherapy_clinical_trial_1455923

About Author

Anusha     aeresearch.net


As a voracious reader and thinker, employing words has always been my preferred method of narration. Anusha’s conviction that a drop of ink possesses the ability to influence even the most stubborn minds has been strengthened by completing a Master’s degree in Engl...

Read More